The mechanism of action of satlizumab (Anshiping)

Satralizumab (Satralizumab) is a humanized monoclonal antibody targeting the human IL-6 receptor. It binds to soluble and membrane-bound IL-6 receptors and prevents the signaling cascade and subsequent pro-inflammatory effects associated with its binding to endogenous IL-6. The exact mechanism by which satelizumab exerts its therapeutic effect in neuromyelitis optica spectrum disorder (NMOSD) is unknown, but it is speculated that it may involve inhibition of IL-6-mediated signaling by binding to soluble and membrane-bound IL-6 receptors. IL-6 may also play a role in increasing blood-brain barrier permeability, allowing autoantibodies and pro-inflammatory mediators to penetrate into the central nervous system.